Return to homepagePandemic Pact

Bundibugyo Ebolavirus Vaccine Candidate Using mRNA Platform

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2026

  • Known Financial Commitments (USD)

    $0

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Principal Investigator

    N/A

  • Research Location

    Congo (DRC), Uganda

  • Lead Research Institution

    Moderna

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CEPI committed up to US$50 million to Moderna to support preclinical testing and Phase 1 clinical trials of a Bundibugyo ebolavirus vaccine candidate. Funding will also support simultaneous manufacturing of doses to allow rapid progression to large-scale Phase 2/3 studies if early clinical results are successful. The vaccine candidate uses Moderna's mRNA platform and builds upon existing research on related Ebola viruses.